|
|
 |
 |
Search
Sign in
Information for
This is an AstraZeneca International website for healthcare professionals.
The site is not intended for the following audiences who should use the links below:
ProstateLine
BreastCancerSource
|
|
|
 |
 |
|
 |
 |
23 July 2008
|
Prostate cancer survival shortened with BRCA2 mutation
|
MedWire News: Prostate cancer patients with a BRCA2 mutation have a significantly shorter survival than those with a BRCA1 mutation, say US and Canadian scientists who suggest that targeted chemotherapies to treat such patients may be necessary.
Previous studies have indicated that men with BRCA2 mutations have an increased risk for developing prostate cancer, and that carriers have poorer survival than prostate cancer patients without the mutation.
To compare survival among prostate cancer patients with BRCA2 and BRCA1 mutations, S Narod, from the University of Toronto in Ontario, Canada, gathered data on age at diagnosis and age at death or current age from 182 prostate cancer patients from families with a BRCA2 mutation and from 119 patients from families with a BRCA1 mutation.
The average age at diagnosis was comparable between the BRCA1 and BRCA2 groups, at 66.9 years and 67.1 years, respectively. Median survival, 5-year overall survival, 10-year survival, and 15-year survival in the two groups was 8.0 years versus 4.0 years, 57% versus 39%, 47% versus 25%, and 35% versus 12%, respectively.
Analysis revealed that the risk for all-cause mortality, adjusted for age, was significantly greater in the BRCA2 mutation group than in the BRCA1 group, at a hazard ratio of 1.7, the team reports in the British Journal of Cancer.
They conclude: "It will be a matter of considerable interest to see whether or not the men with prostate cancer and a BRCA2 mutation benefit from targeted chemotherapy."
Br J Cancer 2008; 99: 371-374
http://www.nature.com/bjc/journal/v99/n2/abs/6604453a.html
|
|
|
 |
 |
|
 |
Home
E-mail this story to a friend